Peptide rules
Can a doctor prescribe Ipamorelin?
Short answer
As of FDA's list updated May 14, 2026, Ipamorelin is not on FDA's list of ingredients compounding pharmacies may use while FDA reviews them. FDA had placed it in Category 2 (significant safety risks); the nomination was later withdrawn, so it does not appear in any category. Not right now: it is not on FDA's current list of ingredients a compounding pharmacy may use.
Also called: Ipamorelin acetate.
Where FDA's list stands
As of FDA's list updated May 14, 2026, Ipamorelin is not on FDA's list of ingredients compounding pharmacies may use while FDA reviews them. FDA had placed it in Category 2 (significant safety risks); the nomination was later withdrawn, so it does not appear in any category.
FDA sorts ingredients it is reviewing for pharmacy compounding into three groups. This one was first placed in Category 2 (significant safety risks), then the person who asked FDA to review it withdrew that request. FDA's current list does not place a withdrawn ingredient in any category, which is different from being cleared or banned: it simply is not part of this review process right now.
Large outsourcing pharmacies: FDA separately lists Ipamorelin among ingredients that raise significant safety risks for outsourcing facilities (called 503B facilities), added September 29, 2023. FDA safety-risk list
What this means if you're looking for a clinician
Ask any clinic which peptides it prescribes, whether each one is FDA-approved or compounded, and which state-licensed pharmacy fills it. A clinic that prescribes Ipamorelin should be able to tell you where its pharmacy sources the ingredient from.
Find a licensed clinician for my state Online peptide doctors
Sources
FDA: Certain bulk drug substances for use in compounding that may present significant safety risks
“This list of bulk drug substances previously in category 2 of the interim policies were withdrawn by the nominators.” Source
Frequently asked questions
Can a doctor prescribe Ipamorelin?
As of FDA's list updated May 14, 2026, Ipamorelin is not on FDA's list of ingredients compounding pharmacies may use while FDA reviews them. FDA had placed it in Category 2 (significant safety risks); the nomination was later withdrawn, so it does not appear in any category. Not right now: it is not on FDA's current list of ingredients a compounding pharmacy may use.
What does "Nominated, then withdrawn" mean?
FDA had sorted it into a review category, then the nomination was withdrawn, so it is not in any category on FDA's current list.
Is Ipamorelin on FDA's safety-risk list?
Yes, for large outsourcing pharmacies (503B facilities): FDA lists Ipamorelin among ingredients that raise significant safety risks, added September 29, 2023.
Is this legal or medical advice?
No. This page explains public FDA information in plain words. It is not legal or medical advice, and rules can change. Talk to a licensed clinician and check the linked FDA pages yourself.
This page explains public FDA information in plain words. It is not legal or medical advice.